The percentage of technically satisfactory Pap tests, from women with a cervix, reported as including an endocervical component was as follows:
| Year | Quarter | % with an Endocervical Component |
|---|---|---|
| 2013 | 1st | 72.8% |
| 2nd | 72.4% | |
| 3rd | 72.5% | |
| 4th | 71.9% | |
| 2014 | 1st | 72.1% |
| 2nd | 72.3% | |
| 3rd | 72.5% | |
| 4th | 71.8% | |
| 2015 | 1st | 71.1% |
| 2nd | 71.0% | |
| 3rd | 70.3% | |
| 4th | 69.7% | |
| 2016 | 1st | 69.9% |
| 2nd | 70.7% | |
| 3rd | 70.2% | |
| 4th | 69.8% | |
| 2017 | 1st | 69.5% |
| 2nd | 66.5% | |
| 3rd | 64.9% | |
| 4th≠ | 64.7% |
Compass HPV DNA tests are not relevant to the data in the above table.
≠ Quarter 4 2017 is for the two month period 01.10.2017 to 30.11.2017 only and includes pre-renewal Cytology and Compass tests. There are 138 test results excluded from the total as the results were never received by the VCSR.
The decline in the proportion of Cytology tests with an endocervical component over time is statistically significant when comparing data for the calendar years of 2012 and 2017*. Over this five year period the proportion of Cytology tests with an endocervical component declined in 2012 from 73.6% (95%CI 73.5%-73.7%) to 66.6% (95%CI 66.5%-66.7%) in 2017 (p<.00001).
No national standards have been set in relation to the proportion of Cytology tests that should include an endocervical component.
*Calendar years 2012 and 2017 are for the period 1 January to 30 November only